Preventing nonvertebral osteoporotic fractures with extended-interval bisphosphonates: Regimen selection and clinical application

MedGenMed Medscape General Medicine

Volumn 11, Issue 1, 2009, Pages

  Cole, Raymond E ^a,c   Harris, Steven T ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Osteoporosis Testing Center of Michigan   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM; IBANDRONIC ACID; IBUPROFEN; PARACETAMOL; PLACEBO; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE;

BONE DENSITY; BONE NECROSIS; CLINICAL ASSESSMENT; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIET SUPPLEMENTATION; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; FRAGILITY FRACTURE; GASTROINTESTINAL DISEASE; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HUMAN; LIFESTYLE; MEDICAL DECISION MAKING; MEDLINE; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT SELECTION; POSTMARKETING SURVEILLANCE; POSTMENOPAUSE OSTEOPOROSIS; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK REDUCTION; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; ANIMAL; DELAYED RELEASE FORMULATION; DRUG ADMINISTRATION; FEMALE; FRACTURE;

ANIMALS; DELAYED-ACTION PREPARATIONS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 58449126956     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008.
2. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22:465-475.
3. Fink HA, Ensrud KE, Nelson DB, et al. Disability after clinical fracture in postmenopausal women with low bone density: the fracture intervention trial (FIT). Osteoporos Int. 2003;14:69-76.
4. Leibson CL, Tosteson AN, Gabriel SE, Ransom JE, Melton LJ. Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc. 2002;50:1644-1650.
5. Mazanec D. Osteoporosis screening: time to take responsibility. Arch Intern Med. 2004;164:1047-1048.
6. Gourlay M. Osteoporosis management: out of subspecialty practice and into primary care. Am Fam Physician. 2004;70:1219-1220.
7. Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA [published online ahead of print February 22, 2008]. Osteoporos Int. 2008;19:449-458.
8. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX® and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19:385-397.
9. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007;18:1033-1046.
10. Kanis JA. FRAX® WHO Fracture Risk Assessment Tool. Available at http://www.shef.ac.uk/FRAX/index.htmAccessed March 3, 2008.
11. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81:1013-1022.
12. Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin. 2005;21:1895-1903.
13. Lewiecki EM, Babbitt AM, Piziak VK, Ozturk Z, Bone HG. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate in women with previous intolerance to oral bisphosphonates: a 12-month, open-label prospective evaluation. Clin Ther. 2008;30:605-621.
14. McClung M, Recker R, Miller P, et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone. 2007;41:122-128.
15. Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone. 2007;40:1238-1243.
16. Chesnut IC, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241-1249.
17. Marcus R, Wong M, Heath H3rd, Stock JL. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev. 2002;23:16-37.
18. Zizic TM. Pharmacologic prevention of osteoporotic fractures. Am Fam Physician. 2004;70:1293-1300.
19. McCarus DC. Fracture prevention in postmenopausal osteoporosis: a review of treatment options. Obstet Gynecol Surv. 2006;61:39-50.
20. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008;148:197-213.
21. Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int. 2002;71:103-111.
22. Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano). 2000;12:1-12.
23. Wells G, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008:CD004523.
24. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008:CD001155.
25. Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int. 2007;18:25-34.
26. Grima DT, Papaioannou A, Thompson MF, Pasquale MK, Adachi JD. Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis. Osteoporos Int. 2008;19:687-697.
27. Curtis JR, Westfall AO, Cheng H, Saag KG, Delzell E. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction [published online ahead of print October 23, 2008]. Osteoporos Int. 2008.
28. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-1822.
29. Delmas PD, Benhamou CL, Man Z, et al. Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporos Int. 2008;19:1039-1045.
30. Delmas PD, McClung MR, Zanchetta JR, et al. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone. 2008;42:36-42.
31. Eisman JA, Civitelli R, Adami S, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol. 2008;35:488-497.
32. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799-1809.
33. Miller PD, Epstein S, Sedarati F, Reginster JY. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin. 2008;24:207-213.
34. Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis. 2006;65:654-661.
35. Stakkestad JA, Lakatos P, Lorenc R, Sedarati F, Neate C, Reginster JY. Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension [published online ahead of print January 8, 2008]. Clin Rheumatol. 2008;27:955-960.
36. Adachi J, Wells G, Papapoulos S, Cranney A, SCIENCE Meta-Analysis Group. A meta-analysis of individual patient data: significant reduction in non-vertebral fractures with high- versus low-dose ibandronate [abstract M428]. J Bone Miner Res. 2007;22:S210.
37. Cranney A, Wells GA, Yetisir E, et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data [published online ahead of print July 29, 2008]. Osteoporos Int. 2008.
38. Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum. 2006;54:1838-1846.
39. Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin. 2008;24:237-245.
40. Recker R, Stakkestad JA, Chesnut CH3rd, et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone. 2004;34:890-899.
41. Miller PD. Non-vertebral fracture risk reduction with oral bisphosphonates: challenges with interpreting clinical trial data. Curr Med Res Opin. 2008;24:107-119.
42. Zaidi M, Epstein S, Harris ST, Kohles JD, Chesnut CH. Progression of efficacy with ibandronate: a paradigm for the development of new bisphosphonates. Ann N Y Acad Sci. 2007;1117:273-282.
43. Harris ST, Blumentals WA, Poston S, Silverman S. Fracture risk with once-monthly oral ibandronate compared with weekly bisphosphonates: primary and sensitivity analyses from the eValuation of IBandronate Efficacy (VIBE) database fracture study. Paper presented at: American Society of Bone and Mineral Research 30th Annual Meeting; September 12-16, 2008; Montreal, Quebec, Canada. Poster 408.
44. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344:333-340.
45. Strampel W, Emkey R, Civitelli R. Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf. 2007;30:755-763.
46. US Food and Drug Administration. Information for healthcare professionals: bisphosphonates. Available at: http://www.fda.gov/cder/ drug/InfoSheets/HCP/bisphosphonatesHCP.htm. Updated January 7, 2008. Accessed February 8, 2008.
47. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479-1491.
48. Grbic JT, Landesberg R, Lin SQ, et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc. 2008;139:32-40.
49. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med. 2007;356:1895-1896.
50. Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med. 2008;168:826-831.
51. Sorensen HT, Christensen S, Mehnert F, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ. 2008;336:813-816.
52. US Food and Drug Administration. Early communication of an ongoing safety review. Bisphosphonates: alendronate (Fosamax, Fosamax Plus D), etidronate (Didronel), ibandronate (Boniva), pamidronate (Aredia), risedronate (Actonel, Actonel w/Calcium), tiludronate (Skelid) and zoledronic acid (Reclast, Zometa). Available at: http://www.fda.gov/cder/ drug/early_comm/bisphosphonates.htm. Updated January 7, 2008. Accessed November 17, 2008.
53. US Food and Drug Administration. Update of safety review follow-up to the October 1, 2007 early communication about the ongoing safety review of bisphosphonates. Bisphosphonates: alendronate (Fosamax, Fosamax Plus D), etidronate (Didronel), ibandronate (Boniva), pamidronate (Aredia), risedronate (Actonel, Actonel w/Calcium), tiludronate (Skelid) and zoledronic acid (Reclast, Zometa). Available at: http://www.fda.gov/cder/ drug/early_comm/bisphosphonates_update_200811.htm. Updated November 12, 2008. Accessed November 17, 2008.
54. Croom KF, Scott LJ. Intravenous ibandronate: in the treatment of osteoporosis. Drugs. 2006;66:1593-1601.
55. Kamel HK. Update on osteoporosis management in long-term care: focus on bisphosphonates. J Am Med Dir Assoc. 2007;8:434-440.
56. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med. 2005;165:2414-2419.
57. Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int. 2006;17:1645-1652.
58. Cooper A, Drake J, Brankin E. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract. 2006;60:896-905.
59. Emkey R, Silverman S, Harley C, Barr CE, Poston S. Women are more persistent with monthly ibandronate versus weekly bisphosphonates: results from a retrospective database [abstract]. Osteoporos Int. 2007;18:S226.